Evidence map›Paper›PMID 39691079›Full record

ArticleFuture oncology (London, England)2024

Genomic characteristics of PD-L1-Induced resistance to EGFR-TKIs in lung adenocarcinoma.

Guangming Yi, Fanghao Cai, Liangzhong Liu, Rongxin Liao, Xuan Jiang, Zhenzhou Yang, Xiaoyue Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Guangming YiDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Fanghao CaiDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Liangzhong LiuDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rongxin LiaoDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Xuan JiangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Zhenzhou YangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.ORCID 0000-0003-2496-1992
Xiaoyue ZhangDepartment of Cancer Center, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe co-occurrence of PD-L1 positivity and EGFR mutations in advanced NSCLC often limits EGFR-TKIs effectiveness, with unclear mechanisms.

methodsWe analyzed 103 treatment-naive EGFR-mutant LUAD patients from three centers, assessing PD-L1 expression and performing NGS analysis.

resultsSMO mutations and MET amplification were significantly higher in the PD-L1 ≥ 1% group versus PD-L1 < 1% group (SMO: 8% vs. 0%,

conclusionThis study elucidates the genomic characteristics of PD-L1-induced resistance to EGFR-TKIs. For patients with concurrent mutations in EGFR and PD-L1 expression, a first-line treatment strategy combining EGFR-TKIs with chemotherapy may offer a more effective alternative.

Indexed as

Adenocarcinoma of LungB7-H1 AntigenDrug Resistance, NeoplasmLung NeoplasmsProtein Kinase InhibitorsAdultAgedAged, 80 and overBiomarkers, TumorErbB ReceptorsFemaleGenomicsHumansMaleMiddle AgedMutationB7-H1 AntigenBiomarkers, TumorCD274 protein, humanEGFR protein, humanErbB ReceptorsMET protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-metchemotherapydrug resistanceepidermal growth factor receptor (EGFR)Lung adenocarcinoma (LUAD)Programmed Death-Ligand 1 (PD-L1)

Identifiers

PMID39691079
PMCPMC11776857

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.